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Abstract
Objective: To investigate the spectrum of antecedent infections in Chinese
patients with Guillain-Barre syndrome (GBS) and analyze the infections-related
clinical phenotypes locally. Methods: A prospective case-control study of 150
patients diagnosed with GBS and age- and sex-matched neurological and
healthy controls was performed to investigate recent infections of 14 pathogens
serologically and collect the clinical data during a follow-up of 12 months.
Results: In total, 53% of patients with GBS had a positive serology for recent
infection, including Campylobacter jejuni (27%), influenza A (17%) and B
(16%), hepatitis A virus (5%), dengue virus (3%), cytomegalovirus (3%),
Epstein–Barr virus (3%), Mycoplasma pneumoniae (2%), herpes simplex virus
(2%), varicella-zoster virus (1%), and rubella virus (1%). Serology for infec-
tions of hepatitis E virus, Haemophilus influenzae, and Zika virus was negative.
There was a higher frequency of C. jejuni, influenza A, influenza B, and hepati-
tis A virus infections in GBS patients than both the neurological and healthy
controls. C. jejuni infection was more frequent in younger GBS patients and
was associated with antibodies against GM1, GalNAc-GD1a, and GM1:galacto-
cerebroside complex. Influenza B infection was associated with a pure motor
form of GBS. Interpretation: C. jejuni, influenza A, influenza B, and hepatitis
A virus serve as the most common cause of antecedent infections in GBS
locally. Influenza B-related GBS may represent a pure motor phenotype. Differ-
ences in the infectious spectrum worldwide may contribute to the geographical
clinical heterogeneity of GBS.
Introduction
Guillain-Barre syndrome (GBS) is an immune-mediated
polyradiculoneuropathy characterized by a rapidly pro-
gressive flaccid paresis. Recent evidence supports GBS as
a spectrum disorder with regional variation and signifi-
cant heterogeneity including clinical presentation, electro-
physiology, and outcome.1,2 Two thirds of the patients
complained of antecedent infections before the onset of
neurological signs.3 Some antecedent infections were asso-
ciated with various clinical phenotypes in GBS. Typically,
Campylobacter jejuni bearing the gangliosides-like lipo-
oligosaccharides (LOS) accounts for the pathogenesis of
axonal GBS, particularly acute motor axonal neuropathy.4
Cytomegalovirus (CMV) infection is associated with sev-
ere motor sensory deficits, demyelination, and antibodies
to the ganglioside GM2.3 Mycoplasma pneumoniae infec-
tion is associated with anti-galactocerebroside (GalC)
antibodies and pediatric GBS.5 Global variation in infec-
tion burden may at least in part explain the regional dif-
ferences in clinical presentation and subtype of GBS. In
the 1990s, a study from Northern China reported axonal
2510 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
GBS as the major subtype in China associated with a high
frequency of C. jejuni infection.6 More recent studies, how-
ever, showed that currently demyelinating GBS was the
predominant subtype in both Northeastern and Southern
China.7,8 The rapid changes in the socioeconomic status of
China may have influenced the exposure to infections and
resulted in a shift of the predominant GBS subtype. Fur-
thermore, many GBS patients developed liver dysfunction
before treatment without obvious causes, that may be
related to specific types of antecedent infections.9 The cur-
rent study aimed to investigate the spectrum of GBS-re-
lated antecedent infections in a Chinese local area and
analyze the infection-related clinical features.
Methods
Patients and blood samples
This study was performed in the Affiliated Hospital of Jin-
ing Medical University, a central hospital regionally in
Southwest of Shandong Province, Northern China, where
it has a population of 17.1 million with an urban–rural
ratio of 1.19. Written informed consent was obtained from
all participants, and study procedures were approved by
the local Ethics Committee (reference 2013B017 and
2016B006). From October 2013 to June 2017, a total of
150 consecutive patients meeting the diagnostic criteria
for GBS and its variants10,11 from the Affiliated Hospital
of Jining Medical University were included in this study,
of whom 19 also participated in the International GBS
Outcome Study.12 For each participant, the pretreatment
serum was collected and kept at 80°C until use. The
clinical data include: age, sex, upper respiratory tract
infection or gastrointestinal infection within 4 weeks
before developing neurological signs, motor and sensory
deficits, cranial nerve involvement, ataxia, tendon reflex,
pain, mechanical ventilation, nerve conduction study
(NCS) within 2 weeks after onset,13 albuminocytological
dissociation in cerebrospinal fluid (CSF), and GBS disabil-
ity score (GBS-DS)14 at nadir and 12 months. The disabil-
ity score at 12 months was obtained from 146 (97%) of
the patients by a telephone follow-up or outpatient revisit.
No follow-up NCS was performed for the patients. Four
patients were lost to follow-up. To explore the relation
between antecedent infection and liver function, data of
liver function tests from patients before treatment were
also collected. For the study of pretreatment liver dysfunc-
tion, 18 of the patients were excluded because of one or
more of the reasons below: with a previous diagnosis of
liver diseases, alcohol abuse or recent intake of liver-toxic
or liver enzyme-inducing drugs, with definite factors
resulting in muscle damage, and elevation of transami-
nases. The liver dysfunction was defined as either alanine
aminotransferase or aspartate aminotransferase becoming
1.5 times higher than the upper limit of normal values.
Controls
After the inclusion of each patient with GBS, a sex- and age-
matched inpatient with other neurological diseases (OND)
and sex- and age-matched healthy donors in the same period
were, respectively, selected from the local biological sample
bank of the hospital established from July 2012. Among the
150 OND controls were included patients with a cerebral
infarction (n = 23), cerebral hemorrhage (n = 27), periph-
eral vertigo (n = 28), Bell’s palsy (n = 39), migraine
(n = 15), myasthenia gravis (n = 4), meningitis (n = 3),
Parkinson disease (n = 6), and epilepsy (n = 5). The 150
healthy controls were recruited from the same hospital and
in all heathy controls, organic diseases were ruled out by the
routine medical examination.
Antecedent infectious spectrum detection
A total of 14 infectious agents were selected according to
previous report3 and unpublished data from Department
of Infectious Diseases, Chinese Centre for Disease Con-
trol, including C. jejuni, M. pneumoniae, Haemophilus
influenzae, influenza A and B virus, herpes simplex virus,
varicella-zoster virus, dengue virus, rubella virus, CMV,
Epstein–Barr virus (EBV), hepatitis A virus, hepatitis E
virus, and Zika virus. The details of ELISA kits for detect-
ing the infectious agents are shown in Table S1. The
serum samples were tested according to the manufactory
instructions. To detect IgM antibodies, the serum was
pretreated to remove the IgG antibodies and prevent false
positivity. C. jejuni, influenza A, and influenza B virus
infections were defined as the presence of IgA and/or IgM
antibodies. H. influenzae infection was defined as the
presence of IgG antibodies. Infections of M. pneumoniae,
hepatitis A virus, herpes simplex virus, varicella-zoster
virus, EBV, dengue virus, rubella virus, CMV, hepatitis E
virus, and Zika virus were defined as the presence of IgM
antibodies. The serology for specific infections in the con-
trols was detected only if more than five GBS patients
were positive for this infection as previously described.3
Anti-glycolipid antibody assay
The serum samples of patients with GBS were tested in
duplicate for IgM and IgG antibodies against GM1, GM2,
GM3, GM1b, GD1a, N-acetylgalactosaminyl GD1a (Gal-
NAc-GD1a), GD1b, GT1a, GQ1b, GalC, sulfatide, GM1:
GalC, GM1:sulfatide, GalC:cholesterol, and GalC:sulfatide
complexes as previously described.15 In general, a vinyl
ELISA plate (Corning, ME, USA) was coated with the
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glycolipid or glycolipid complex (5 pmol per well; for gly-
colipid complex, 2.5 pmol each). The serum diluted in
phosphate buffered saline (PBS) (0.1 M, pH 7.4) contain-
ing 0.5% casein (1:500) was added into the plates for incu-
bation overnight at 4°C. After three times of washing with
0.1 M PBS containing 0.05% Tween 20, the plates were
added with horseradish peroxidase-conjugated goat anti-
human IgG (gamma chain) (Thermo Scientific, Rockford,
IL, USA) (1:3000 in PBS containing 0.5% casein) or horse-
radish peroxidase-conjugated goat anti-human IgM (heavy
chain) (Thermo Scientific) (1:10000) and incubated at
37°C for 1 h. After washing the plates with the same wash-
ing buffer, the binding of IgG or IgM antibodies was visual-
ized by O-phenylenediamine (Sigma, MO, USA)
developing solution in the darkness for 15 min and then
the reaction was stopped by 2N hydrochloride. The absor-
bance at 492 nm/630 nm (as reference) was measured
using a ChroMate Microplate Reader (Awareness Tech-
nology, Palm City, USA). Each sample was tested with a
blank and negative control for quality control. With refer-
ence to a blank control, the optical density value over 0.1
was considered positive. A positive serology for anti-glycol-
ipid antibodies was defined as the presence of either IgG or
IgM or both.
Data availability
Our data will be shared by request from any qualified
investigator for scientific purposes.
Statistical analysis
Normally distributed continuous data were presented as
means and standard deviations. The categorical variables
were shown as n (%). The difference in the frequency of
infections in patients with GBS and the controls was com-
pared by the Chi-square test or Fisher’s exact test. For
patients with and without infections, the difference in
demographic and clinical features, anti-glycolipid antibod-
ies, and clinical subtypes were compared by Chi-square test
or Fisher’s exact test. The analysis was performed with the
SPSS 20.0 analysis software (IBM, Armonk, NY). A two-
sided P < 0.05 was considered to be significant.
Results
Antecedent infectious spectrum in patients
with GBS
The demographic and clinical features of the patients with
GBS are shown in Table 1. There was no difference in age
or sex between the patients with GBS and the controls. The
mean age of patients with GBS was 51.0; interquartile range
(IQR) was 41 to 64 and the male to female ratio was 1.2
(81/69). For patients with OND and the healthy controls,
the mean age was 51.9 (IQR, 42–64) and 51.3 (IQR, 42–
64), respectively; the sex ratio was both the same 1.2 (81/
69). Of the 150 patients with GBS, 53% (80/150) had posi-
tive serology for either C. jejuni (n = 40, 27%), influenza A
(n = 26, 17%), influenza B (n = 24, 16%), hepatitis A virus
(n = 7, 5%), dengue virus (n = 4, 3%), CMV (n = 4, 3%),
EBV (n = 4, 3%),M. pneumoniae (n = 3, 2%), herpes simplex
virus (n = 3, 2%), varicella-zoster virus (n = 2, 1%), and
rubella virus (n = 1, 1%). There were significant higher
Table 1. Demographic and clinical characteristics of 150 patients
with Guillain-Barre syndrome.
Characteristic n (%)
Age, mean (standard deviation) 51.0 (16.1)
Male/female ratio 1.2 (81/69)
Antecedent infection within 4 weeks
Upper respiratory tract infection 36 (24)
Gastrointestinal infection 19 (13)
Motor deficits
Upper and lower limb weakness 111 (74)
Upper limb weakness only 5 (3)
Lower limb weakness only 11 (7)
None 23 (15)
Sensory deficits 62 (41)
Cranial nerve involvement
Oculomotor weakness 23 (15)
Facial weakness 30 (20)
Bulbar weakness 29 (19)
None 68 (45)
Ataxia 6 (4)
Tendon reflex at the nadir
Hyporeflexia or areflexia 128 (85)
Normal 22 (15)
Pain 13 (9)
Disability score at the nadir
1 35 (23)
2 31 (21)
3 20 (13)
4 45 (30)
5 17 (11)
6 2 (1)
Albuminocytological dissociation in CSF 95/123 (77)
Single nerve conduction study
Primary demyelinating 41/120 (34)
Primary axonal 35/120 (29)
Unclassified 27/120 (23)
Normal 17/120 (14)
Disability score at 12 months
0–1 113/146 (77)
2 13/146 (9)
3 8/146 (6)
4 5/146 (3)
6 7/146 (5)
Pretreatment liver dysfunction 13 (17/132)
CSF, cerebrospinal fluid.
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frequencies of C. jejuni, influenza A, influenza B, and hepatitis
A virus infections in patients with GBS than in the controls
(Table 2). Twenty-six (17%) patients had more than one infec-
tion (Fig. 1). Eighty percent of patients (120/150) were from
rural areas. There was no difference in the frequency of antece-
dent infections in patients with GBS between urban and rural
areas (Table S2). None of the patients had positive serology for
hepatitis E virus, H. influenza, and Zika virus.
Infection-related clinical features
As shown in Table 3, the comparison was made among
the GBS patients with infection of C. jejuni, influenza A,
and influenza B as well as patients with no infections.
There were significantly younger age and higher frequency
of antecedent diarrhea complaints in patients with C.
jejuni infection than the controls. All seven patients with
preceding influenza B infection had a pure motor GBS
without sensory deficits, which differed from the patients
with infection of C. jejuni, influenza A, and patients with-
out infection (P = 0.037). In addition, these patients with
influenza B infection had no ataxia (0/7), no pain (0/7),
no demyelinating subtypes (0/5) and high frequency of
mechanical ventilation (2/7, 29%), and pretreatment liver
dysfunction (2/7, 29%). There was no mechanical ventila-
tion (0/11) in GBS patients following influenza A infec-
tion. There was no pretreatment liver dysfunction (0/25)
in GBS patients following C. jejuni infection. With regard
to patients with C. jejuni, influenza A and B virus as well
as without infection, there was no difference in frequency
of patients on cranial nerve involvement, ataxia, tendon
reflex at nadir, pain, mechanical ventilation, electrophysi-
ological classification, and pretreatment liver dysfunction.
Antecedent infections and the clinical
variants
The patients were classified into GBS (n = 125, 83%),
Miller Fisher syndrome (MFS) (n = 4, 3%), acute oph-
thalmoparesis (n = 4, 3%), GBS/MFS overlap (n = 2,
1%), bifacial weakness with paraesthesias (n = 2, 1%),
acute pharyngeal weakness (n = 2, 1%), and pure sensory
subtype (n = 11, 7%). As shown in Figure 2, there was
no association between these variants of GBS and the
presence of specific types of preceding infection.
Antecedent infections and anti-glycolipid
antibodies
As shown in Table S3, the frequency of antibodies against
glycolipids and glycolipids complex in 150 of patients
Table 2. Frequency of antecedent infections in patients with Guillain-Barre syndrome and the controls.
GBS (n = 150)
OND controls
(n = 150) OR (95% CI) P value HC(n = 150) OR (95% CI) P value
No infection 70 (47) 128 (85) Reference 132 (88) Reference
Campylobacter jejuni 40 (27) 10 (7) 7.3 (3.5, 15.5) <0.001 13 (9) 5.8 (2.9, 11. 6) <0.001
Influenza A 26 (17) 8 (5) 5.9 (2.6, 13.8) <0.001 10 (7) 4.9 (2.2, 10.7) <0.001
Influenza B 24 (16) 7 (5) 6.3 (2.6, 15.3) <0.001 9 (6) 5.0 (2.2, 11.4) <0.001
Hepatitis A virus 7 (5) 3 (2) 4.3 (1.1, 17.0) 0.027 0 (0) - -
Dengue virus 4 (3)
Cytomegalovirus 4 (3)
Epstein–Barr virus 4 (3)
Mycoplasma pneumoniae 3 (2)
Herpes simplex virus 3 (2)
Varicella-zoster virus 2 (1)
Rubella virus 1 (1)
The data are shown as n (%).
OR, odds ratio; CI, confidence interval; GBS, Guillain-Barre syndrome; OND, other neurological disease; HC, healthy controls. No infection of the
hepatitis E virus, Haemophilus influenzae, and Zika virus was detected.
Figure 1. The number of patients with more than one infection.
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with GBS was anti-GM1 (39%), anti-GM1b (1%), anti-
GD1a (11%), anti-GD1b (19%), anti-GalNAc-GD1a
(11%), anti-GQ1b (13%), anti-GM1:GalC complex
(23%), anti-GM1:sulfatide complex (20%), and anti-
GalC:sulfatide complex (1%), respectively. There was sig-
nificantly higher frequency of antibodies against GM1,
GalNAc-GD1a, and GM1:GalC complex in patients fol-
lowing C. jejuni infection than patients without infections
(P = 0.002, P < 0.001, and P = 0.019, respectively). The
anti-GalC:sulfatide complex antibodies were IgG subtype
and were detected in one patient with influenza A and M.
pneumoniae infections. For patients with anti-GM1 IgG
antibodies, 40% (23/58) had cross-reaction with GM1:
GalC complex and 60% solely bound to GM1. For
patients with anti-GM1:GalC complex IgG antibodies,
26% (9/34) showed complex-independent, 24% (8/34)
showed complex-enhancement, 18% (6/34) showed com-
plex-attenuated, and 32% (11/34) showed complex-de-
pendent. For patients with anti-GM1:sulfatide complex
IgG antibodies, 43% (13/30) showed complex-indepen-
dent, 13% (4/30) showed complex-enhancement, 17% (5/
30) showed complex-attenuated, and 27% (8/30) showed
complex-dependent.
Discussion
We hereby demonstrated that C. jejuni, influenza A, influ-
enza B, and hepatitis A virus currently served as the most
common cause of antecedent infections in GBS in the
Southwest of Shandong Province, Northern China. The
proportion of patients following infections of CMV, EBV,
and M. pneumoniae only accounted for less than 5% of
the total patients, respectively. Infections of dengue virus,
herpes simplex virus, varicella-zoster virus, and rubella
virus were also detected but only in a minority of patients
and not higher than in controls. The proportion of
patients with C. jejuni infection in our region (27%) was
similar to those patients reported in Dutch (32%)3 and
the UK(26%)16 but lower than those reported in Bangla-
desh (57%)17 and a previous study from Northern China
(66%).6 From 2000 to 2018, the average life expectancy
locally increased from 73.9 to 78.1 (unpublished data).
The changes in the proportion of GBS patients with C.
jejuni infection in China may reflect the improved healthy
conditions of this country and be related to the rapid
development of society and the economy.18 The C. jejuni
infection has a strong relation with axonal GBS.6,17
Table 3. Antecedent infections and clinical characteristics of patients with Guillain-Barre syndrome.
Characteristic
No infection
(n = 70)
Campylobacter jejuni
(n = 25)
Influenza A
(n = 11)
Influenza B
(n = 7)
P
value*
Age, mean (standard deviation) 51.8 (15.3) 44.6 (15.3) 60.6 (10.3) 54.3 (19.3) 0.03
Antecedent infection within 4 weeks
Upper respiratory tract infection 16 (23) 7 (28) 3 (27) 2 (28) 0.032
Gastrointestinal infection 6 (9) 8 (32) 0 (0) 0 (0)
None 48 (68) 10 (40) 8 (73) 5 (72)
Motor deficits 61 (87) 21 (84) 9 (82) 6 (86) 0.969
Sensory deficits 35 (50) 8 (32) 6 (55) 0 (0) 0.037
Cranial nerve involvement 41 (59) 15 (60) 6 (55) 6 (86) 0.766
Ataxia 4 (6) 1 (4) 1 (9) 0 (0) 0.846
Hyporeflexia or areflexia at nadir 62 (89) 24 (96) 9 (82) 5 (71) 0.276
Pain 3 (4) 3 (12) 2 (18) 0 (0) 0.227
Mechanical ventilation 9 (13) 3 (12) 0 (0) 2 (29) 0.353
Disability score at nadir
˂4 35 (50) 13 (52) 8 (73) 3 (43) 0.524
≥4 35 (50) 12 (48) 3 (27) 4 (57)
Albuminocytological dissociation in
CSF
41/58 (71) 18/20 (90) 9/9 (100) 5/5 (100) 0.053
Single nerve conduction study
Primary demyelinating 21/57 (37) 5/17 (29) 3/9 (33) 0/5 (0) 0.661
Primary axonal 14/57 (25) 7/17 (41) 2/9 (22) 2/5 (40)
Unclassified 13/57 (23) 2/17 (12) 3/9 (33) 1/5 (20)
Normal 9/57 (16) 3/17 (18) 1/9 (11) 2/5 (40)
Disability score at 12 months
˂2 52/68 (76) 18 (72) 9/10 (90) 5 (71) 0.708
≥2 16/68 (24) 7 (28) 1/10 (10) 2 (29)
Pretreatment liver dysfunction 12/63 (19) 0/25 (0) 2/11 (18) 2/7 (29) 0.109
CSF, cerebrospinal fluid. If not specified, the data are shown as n (%).
*The P value showed the difference among the four groups.
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Reduced proportion of patients with C. jejuni infection
may contribute to the predominant GBS subtype in China
changed from axonal GBS in the 1990s to demyelinating
GBS in 2010s. Notably, seven patients with C. jejuni infec-
tion complained of upper respiratory tract symptoms.
The infection of C. jejuni may breakdown the host
immune balance and increase the host susceptibility to
the infectious diseases.19 It is possible that C. jejuni infec-
tion may cause other infections beyond our study, which
accounts for the upper respiratory tract symptoms in the
patients.
Patients with GBS in our cohort study displayed infec-
tion-related clinical features. Being similar to the Dutch
study,3 patients with C. jejuni infection had more often
complaints of diarrhea than other patients. Although a
cohort study from Bangladesh showed no association
between the age of patients with GBS and C. jejuni infec-
tion,17 our study showed that C. jejuni infection was more
frequent in younger patients with GBS, which may reflect
a special dietary construct increasing the risk of C. jejuni
infection in the youth population. Similarly, a recent
international study in GBS showed that patients with the
axonal subtype are younger than other patients.2 How-
ever, in our study, there was no difference in frequency of
electrophysiological subtypes between patients with C.
jejuni and other infections. Notably, GBS patients follow-
ing influenza B infections displayed pure motor deficits
and high risk of needing mechanical ventilation (2/7,
29%) while GBS patients following influenza A infections
had no need for mechanical ventilation (0/11) and rela-
tively low frequency of patients with GBS-DS ≥ 4 at
nadir. Our study supported influenza B-related GBS as a
severe phenotype of pure motor deficits while influenza
A-related GBS mainly presents as a mild clinical pheno-
type. Our results were similar to a previous study that
none of influenza A-related GBS (0/8) needed mechanical
ventilation while half of the GBS patients following influ-
enza B infection (2/4) needed mechanical ventilation.20
The exposure to different types of preceding infection in
combination with host factors among different regional
or ethnic groups may result in the geographical clinical
heterogeneity in GBS worldwide.
Previously, the relation between C. jejuni infection and anti-
bodies against gangliosides, including GM1, GM1b, GD1a,
GalNAc-GD1a, and GQ1b, has been well established in
GBS.21,22 In our region, there was a strong correlation between
C. jejuni infection and anti-GM1, anti-GalNAc-GD1a, and
anti-GM1:GalC complex antibodies. The gene polymorphism
of cst-II, encoding a sialyltransferase in C. jejuni, leads to the
biosynthesis of different gangliosides-mimicking LOS.22,23 C.
jejuni strains with cst-II (Asn51) regularly express the GQ1b-
like LOS while the strains with cst-II (Thr51) express more
GM1-like and GD1a-like LOS.22 Typically, IgG antibodies
against GQ1b were associated with MFS while the IgG anti-
bodies against GM1 and GD1a were associated with axonal
GBS.24,25 High incidence of MFS was previously reported in
East Asia, especially Japan (up to 26%);2,26 however, there was
much lower frequency of MFS in both our current study (3%)
and a large multicenter study from Southern China (12%).8
Our results supported C. jejuni with cst-II (Thr51), bearing
GM1-like LOS, as one of the causative pathogens in our region,
which deserves a further study using C. jejuni samples from the
patients. Moreover, none of the patients in our cohort were
detected with H. influenzae infection, which was frequently
seen in patients with MFS.27 The regional infectious spectrum
may partly explain why there was a low frequency of MFS in
China.
Liver injury in patients following influenza A and B
infections has been described in both the cohort study
and case report.28,29 Some GBS-related pathogens includ-
ing EBV, varicella-zoster virus, hepatitis A virus, and hep-
atitis E virus were able to trigger the autoimmune
response against liver.30–32 Although pretreatment liver
dysfunction has been reported for a long time,9 it remains
unknown that the pretreatment liver dysfunction in GBS
was caused by antecedent infections or GBS itself. In this
study, 13% (17/132) of the patients were detected with
pretreatment liver dysfunction at entry. Although the dif-
ference in frequency of pretreatment liver dysfunction
among patients with and without infections was not sig-
nificant, GBS patients following influenza B virus infec-
tion displayed more susceptibility to pretreatment liver
dysfunction. Our study supported antecedent infection as
one cause of pretreatment liver dysfunction in GBS
patients. However, 19% of the patients without infection
also had pretreatment liver dysfunction. It cannot be
Figure 2. Antecedent infections and the clinical variants of Guillain-
Barre syndrome. As shown, Guillain-Barre syndrome (GBS) constitutes
the major subtypes in all of the patients with and without infections
except that one patient with Mycoplasma pneumoniae had the
bifacial weakness with paraesthesias. *There was no difference in
frequency of GBS among the patients with and without infections
(partition of Chi-square test, P = 0.607). MFS, Miller Fisher syndrome.
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excluded that some other pathogens beyond our study
were associated with liver dysfunction in patients with
GBS. None of the GBS patients with C. jejuni infection
had pretreatment liver dysfunction, which needs further
confirmation by other cohort studies.
In conclusion, this is the first study to report the antece-
dent infectious spectrum in patients with GBS in China.
We firstly reported influenza B-related GBS as a pure
motor phenotype. C. jejuni serves as the predominant cause
of antecedent infections in patients with GBS in our region,
but the frequency is much lower than 30 years ago. The
regional infectious spectrum contributed to the clinical
heterogeneity of GBS. Our results deserve further confirma-
tion by other larger cohort studies.
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